FDA should approve emergency contraceptive Plan B quickly to demonstrate its independence

May 18, 2006

Andrew von Eschenbach, acting US Food and Drug Administration (FDA) commissioner, should move quickly to approve emergency contraceptive Plan B to show he has the independence needed to head the organisation, states an editorial in this week's issue of The Lancet. von Eschenbach, former Director of the US National Cancer Institute (NCI), is President George W Bush's choice to lead the FDA. The Lancet believes he would bring considerable expertise and experience to the post. However, the FDA must be led by a commissioner willing to take independent stands, following the best judgment of his expert staff and scientific advisors, even when that means incurring the wrath of patient groups, industry, Congress, and the White House, states the editorial. For more than a year, the FDA has refused to issue a decision on an application to make Plan B available to women over age 16 without prescription, apparently to avoid offending anti-abortion supporters of President Bush, who claim that the contraceptive causes an abortion.

The Lancet comments: "Although supporters of Plan B's in the US Senate have blocked his confirmation until the FDA issues a ruling, as acting FDA commissioner von Eschenbach has refused to do so. His failure to issue a decision undermines both his credibility and that of the agency. von Eschenbach should move quickly to approve Plan B and show he has independence needed to be an effective leader of the FDA."

See also World Report on the FDA and Profile on Andrew von Eschenbach.
Contact: The Lancet press office T) 0207 424 4949/4249 pressoffice@lancet.com


Related Contraceptive Articles from Brightsurf:

UC research finds low rates of contraceptive use in women with kidney failure
New research from the University of Cincinnati finds that women with kidney failure have low rates of contraceptive use.

Use of emergency contraceptive pills among Scandinavian women
Use of emergency contraceptive pills (ECPs) is common among Scandinavian women, with one-third having used them at least once, according to a study published in Acta Obstetricia et Gynecologica Scandinavica.

Providing contraceptive care in the pediatric emergency department
A new study found that two-thirds of female adolescents ages 16-21 seen in a pediatric Emergency Department (ED) were interested in discussing contraception, despite having a high rate of recent visits to a primary care provider.

Stopping sperm in its tracks: latest progress in the hunt for a male contraceptive
Researchers at the University of Dundee have developed an unrivalled, fully automated robotic screening system which allows them to rapidly test the effect of drugs and other chemicals on human sperm.

Once-a-month oral contraceptive could improve patient adherence
Researchers have created a new ingestible drug delivery platform that expands in the stomach and could safely deliver a contraceptive over one month when tested in pigs.

Fertilization discovery could lead to new male contraceptive, help infertile couples
An unexpected discovery about fertilization reveals new insights into how sperm and egg fuse and could have major implications for couples battling infertility -- and may lead to a future male contraceptive.

Contraceptive drug shows promise for preventing and regressing cervical cancer
A new study in The American Journal of Pathology, published by Elsevier, reports that medroxyprogesterone acetate (MPA), the active ingredient in the common contraceptive injection Depo-Provera, was effective in preventing the development of cervical cancer in mice with precancerous lesions.

Contraceptive jewelry could offer a new family planning approach
Family planning for women might one day be as simple as putting on an earring.

Long-acting contraceptive designed to be self-administered via microneedle patch
A new long-acting contraceptive designed to be self-administered by women may provide a new family planning option, particularly in developing nations where access to healthcare can be limited, a recent study suggests.

First trial of dapivirine ring with both ARV and contraceptive finds no safety concerns
In the first clinical study of a vaginal ring that releases the antiretroviral drug dapivirine as well as a contraceptive hormone, there were no safety concerns and the ring was well-tolerated.

Read More: Contraceptive News and Contraceptive Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.